Invesco Ltd. vs Health Care Select Sector SPDR Fund — how do they compare? Invesco Ltd. trades at $29.96 (market cap $13.15B), while Health Care Select Sector SPDR Fund trades at $159.68. The key difference: Invesco Ltd. pays a 2.9% dividend while Health Care Select Sector SPDR Fund pays none, and Invesco Ltd. is trading nearer its 52-week high, Health Care Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| IVZ | XLV | |
|---|---|---|
Market Cap | $13.15B | — |
Sector | Financials | — |
52-Week High | $30.30 | $164.48 |
52-Week Low | $20.20 | $129.01 |
Enterprise Value | $23.39B | — |
Dividend Yield | 2.9% | — |
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $29.57, down 0.2% on the day, with a bullish technical outlook supported by moving averages despite overbought RSI readings. The company reported revenue growth to $6.38B in 2025 but posted a net loss of -$281.70M, reflecting margin pressures. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Positive cash flow from operations of $1.53B in 2025 highlights operational strength, while analyst sentiment leans neutral with a consensus price target of $30.64.
The stock presents a cautious opportunity with solid revenue growth and improving cash flows offset by profitability challenges. Near-term catalysts include potential earnings recovery and dividend payments, but risks from competitive pressures and macroeconomic volatility warrant careful monitoring. The current price near the consensus target suggests limited upside without fundamental improvements.
XLV trades at $159.25, down 1.14% on the day, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The healthcare ETF faces mixed sentiment with recent positive sector upgrades from State Street Investment Management but concerns about sector headwinds during earnings season. Support levels cluster around $158-160, while resistance sits at $163-165.
The healthcare sector offers defensive characteristics amid market volatility, with XLV providing diversified exposure. Key risks include patent cliffs for major holdings and election-year policy uncertainty. Analyst sentiment is cautiously optimistic given the sector's stability and innovation pipeline, though relative performance versus technology remains a concern.
Trailing returns across standard periods
Latest headlines on both assets
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →